Liên hệ chúng tôi
Về công ty
Cancer Advances is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio. Cancer Advances is a wholly owned subsidiary of Cato BioVentures. The company's lead compound, Polyclonal Antibody Stimulator (PAS), is an immunomodulator used to treat gastrointestinal cancer. Please visit their Product page for more information on what is in development.
US
Không xác định
Chưa xác minh công ty
Minh bạch kinh doanh
- Chưa xác minh thông tin công ty
- Yêu cầu khách hàng của họ đánh giá
- Không trả lời các đánh giá tiêu cực